# Critical Limb Ischemia Rapid Delivery by SurgWerks-CLI Kit and VXP System

> **NCT02538978** · PHASE3 · UNKNOWN · sponsor: **Cesca Therapeutics, Inc.** · enrollment: 224 (estimated)

## Conditions studied

- Critical Limb Ischemia (CLI)

## Interventions

- **BIOLOGICAL:** Autologous Bone Marrow Concentrate (aBMC)
- **BIOLOGICAL:** Placebo Control (diluted autologous peripheral blood)

## Key facts

- **NCT ID:** NCT02538978
- **Lead sponsor:** Cesca Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-01
- **Primary completion:** 2018-12
- **Final completion:** 2019-03
- **Target enrollment:** 224 (ESTIMATED)
- **Last updated:** 2016-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02538978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02538978, "Critical Limb Ischemia Rapid Delivery by SurgWerks-CLI Kit and VXP System". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02538978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*